Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC
August 8th 2023
Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.